The 2008 Mid-Atlantic Bio takes place October 22, 2008 – October 24, 2008 at the Westfields Marriott Washington Dulles in Chantilly. Listed below are the 2008 Mid-Atlantic Bio exhibitor profiles.
For in-depth information about the 2008 Mid-Atlantic Bio, visit http://midatlanticbio.org/.
Business Wire is the official news wire for the 2008 Mid-Atlantic Bio. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire’s trade show, conference, and event news resource.
Company: Alba Therapeutics Corporation Date of Presentation: 10/24/2008 Media Contact: Wendy Perrow Phone: 410-319-0780 E-mail: [email protected] Web: www.albatherapeutics.com Alba is focused on the development of therapies to treat autoimmune and inflammatory diseases. Alba's technology platform is based upon the regulation of tight junctions in cell barriers throughout the body. Alba has completed four clinical trials in celiac disease and believes that these studies demonstrate the safety and tolerability of Larazotide Acetate. Alba estimates the worldwide market for its celiac disease therapy could exceed $1 billion. Alba has a major $325 million collaboration with Shire Pharmaceuticals to jointly develop Larazotide Acetate. Alba was founded in 2004 and currently leases space at the University of Maryland BioPark. Alba has attracted over $50 million in investments since its inception. Current investors include SVLS, AltaPartners and Healthcap with additional participation by Red Abbey and MDBED. Company: AparnaBio Date of Presentation: Thursday Oct 23, 2008 Media Contact: Mark Berninger Phone: 301-770-2101 E-mail: [email protected] Web: www.aparnabio.com AparnaBio is a early stage biotech R&D company in Rockville, Maryland, developing research reagent and therapeutic products based on a "tunable" polyamide nanoparticle technology platform that accommodates charged and macromolecular agents and can provide tissue targeting surface decoration. Initial products include in vivo transfection reagents, therapeutic treatment for invasive fungal infection and non-small cell lung cancer. AparnaBio has growing revenues and collaborations with academic and industry laboratories. Company: Avid Radiopharmaceuticals, Inc. Date of Presentation: October 24, 2008 8:30am Media Contact: Laura Liotta (SamBrown Inc) Phone: (610) 353-4545 E-mail: [email protected] Web: www.avidrp.com At Avid, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre- symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This is possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - before symptoms of disease can develop. Company: BioMarker Strategies Date of Presentation: 10/23/2008 Media Contact: Scott Allocco, President Phone: 410-522-1008 E-mail: [email protected] Web: www.biomarkerstrategies.com BioMarker Strategies, a tissue-based cancer diagnostics company at the Johns Hopkins Science+Technology Park in Baltimore, is developing the SnapPath(TM) live tumor cell processing and testing system. This pathology-based medical device will use proprietary methods to automatically process biopsies at the point of care--in a novel manner that preserves dynamic biomarkers that are lost during traditional tumor processing. SnapPath(TM) will also serve as a live cell testing platform for our ex-vivo biomarker tests that are being designed to determine which patients will benefit from specific targeted cancer drugs. The SnapPath(TM) system will facilitate the development of targeted cancer therapeutics and molecular diagnostic tests to help enable personalized medicine for cancer. Company: Calibrant Biosystems, Inc. Date of Presentation: 10/23/2008 Media Contact: Michael L. Salgaller, PhD Phone: 301-977-7900 E-mail: [email protected] Web: www.calibrant.com Calibrant's proteomic technology is pioneering the development of novel therapeutics using the Gemini(TM) discovery and development engine to elucidate disease pathways and protein networks from targeted cells captured from clinical tissue specimens and body fluids. Our technology enables comprehensive and quantitative protein profiling of isolated and homogeneous cell populations from clinically-relevant samples, allowing us to approach the full biology of disease pathogenesis with exquisite sensitivity. Coupled with an integrated bioinformatics suite enabling effective data mining within a biological context, Calibrant's approach provides unique benefits for drug discovery, drug development, and the identification of predictive markers for personalized medicine. Company: Chikujee Therapeutics Date of Presentation: 10/23/2008 Media Contact: Jenny Smith Phone: 240-422-2118 E-mail: [email protected] Web: www.Chikujee.com Chikujee Therapeutics is focused on designing, developing and commercializing next generation therapeutics using our patent-pending class of multifunctional nanoparticles. Chikujee uses NanoBindi(TM) based integrated disease management platform that utilizes our proprietary BOSH-containing polymers. Chikujee Therapeutics has developed product engines that have broad applications in life- sciences, primarily in biopharmaceutical industries. We believe there is significant value in "product engines." The initial focus of Chikujee Therapeutics will be to develop market leading blockbuster products for integrated cancer management that addresses, targeted drug delivery and monitoring, and clinical efficacy of the drugs for cancer using its proprietary multifunctional NanoBindis. Company: Gliknik Inc. Date of Presentation: 10/23/2008 Media Contact: David Block Phone: 410.685.0662 E-mail: [email protected] Web: www.gliknik.com Gliknik is a clinical-stage company developing highly novel products and platforms in immunology and tumor immunology. Stradobodies are monoclonal antibody mimetics changed to enhance tumor cell killing. Stradomers are recombinant proteins that function like IVIG. The company has lead compounds identified in both of these programs. Gliknik's Trojan Peptide Vaccines are therapeutic cancer vaccines designed having learned from cancer therapeutic vaccines that have previously been in patients. Two compounds are in testing in patients with advanced Head and Neck Cancer. The underlying platform is expandable to other tumor types. Gliknik is located at the UM Baltimore BioPark in Baltimore. Company: HemoSonics, LLC Date of Presentation: Thursday, October 23rd Media Contact: William F. Walker, President Phone: 434-962-2269 E-mail: [email protected] Web: www.hemosonics.com HemoSonics is developing a point-of-care (POC) blood analyzer to diagnose and guide the treatment of excessive bleeding and overactive clotting. Ours will be the first POC product capable of quantifying the contributions of coagulation factors and platelets to clotting. We utilize a patented ultrasound-based technology implemented in off- the-shelf electronics, for a compact, low-cost, and easy-to-use system. The diagnostic information provided by our product is critically needed to guide patient care in a variety of clinical settings including the OR, ER, and ICU. The addressable annual market for this product exceeds $3.3B. Company: I3 Oncology, LLC Date of Presentation: 10/23/2008 Media Contact: Mark Ricigliano Phone: (301) 317-7160 E-mail: [email protected] I3 Oncology, LLC is an early stage life science company located in Baltimore, Maryland that offers oncologists a novel approach to dramatically improve the clinical outcome of chemotherapy for treatment refractory cancer patients. Current chemotherapy selection is based on subjective criteria with an efficacy of less than 20% for most cancer patients. Our diagnostic test, Insignia PGx, provides oncologists with the pharmacogenetic basis for chemotherapy selection based on the individual patient's tumor characteristics thereby dramatically improving the clinical outcome. Insignia PGx research was funded by NIH grants and its patents were licensed from Johns Hopkins University. Company: Keraderm LLC Date of Presentation: October 23rd Media Contact: Bill Cumbie Phone: 757-344-8607 E-mail: [email protected] Web: www.keraderm.com Keraderm's innovative light-based technology can treat infections without the serious side effects that many medications and can effectively treat infections caused by drug resistant organisms such as MRSA. Keraderm has obtained patents on its key technologies to treat infections and has a number of additional patent applications pending on refinements of its technology. Published studies indicate that the technology can safely and effectively treat infections. In 2009, Keraderm plans to obtain FDA 510k clearance to commercialize its treatment for nail infections making it the first safe and efficacious phototherapy treatment in this $1.5B market. Company: Midwest Proteomics Date of Presentation: October 23rd 2008 Media Contact: Frank Blainey Phone: (804) 677-3177 E-mail: [email protected] Web: www.midwestproteomics.com Midwest Proteomics is a biomarker discovery group, based in Richmond Virginia, with a proprietary life-sciences software platform that includes advanced validation techniques. The Company's mission is to advance pharmaceutical/biological discovery using computational informatics technology to facilitate novel drug target identification and optimize preclinical studies. In 2008 Midwest Proteomics' software platform was recognized at the Molecular Medicine Symposium, as well as by the Institute for Electrical and Electronics Engineers (IEEE) for advancing biomarker research. Midwest Proteomics' proprietary software and databases embodies the cutting edge of computational biology. Company: Neuronascent, Inc. Date of Presentation: 10/23/2008 Media Contact: Kathleen L. Mattis Phone: 410-258-0935 E-mail: [email protected] Web: www.neuronascent.com Neuronascent Inc. uses a proprietary drug discovery platform to discover and develop novel "neurogenic" small-molecule therapeutics for Alzheimer's disease, depression and ischemia. Lead compounds are in preclinical testing. Studies indicate that our chemically-diverse, orally-active "neurogenic" agents, which are owned by the company for use and composition, promote the formation of new neurons in key areas of the brain that replace damaged neurons, reduce the loss of neurons over time and self-repair brain cells that are injured or become dysfunctional in neurodegenerative diseases. Animal studies show a reversal of cognitive loss in aged mice to young levels Company: OTraces Date of Presentation: Thursday, October 23, 2008 Media Contact: Richard Wathen Phone: 703-967-5450 E-mail: [email protected] Web: www.otraces.com The cancer diagnostic market lacks highly specific and sensitive, yet simple screening blood tests. OTraces, Inc. has combined highly innovative technology developments to produce practical blood tests for such cancers for the first time. The products are fully developed and ready for regulatory approval. OTraces' blood tests are both highly specific and sensitive, with false negative and positive counts of about 5%. This level of performance far exceeds any current screening diagnostic method for cancer. The overall screening market for oncology (Breast, Ovarian, Colon, Prostate, Lung and Melanoma) is estimated to be $3.3, billion and $7.4 billion, worldwide. Company: Supernus Pharmaceuticals, Inc Date of Presentation: 10/24/2008 Media Contact: Jack Khattar Phone: 301-838-2500 E-mail: [email protected] Web: www.supernus.com Supernus is a neuroscience company developing specialty products using its patented and proven technologies and product development capabilities. Supernus is dedicated to improving the lives of people suffering from diseases of the central nervous system. The company's expertise has been built over the past 18 years. Supernus purchased significantly all the assets of Shire Laboratories that was a subsidiary of Shire. Products utilizing Supernus' technologies include Adderall XRy, Carbatroly, Equetroy, Oracea(R), Sanctura(R) XR, Intuniv and Remodulin(R) Oral. Supernus' pipeline includes two epilepsy products (Phase III in 2009) followed by three psychiatry products (Phase II). The company plans on building its commercial organization with dedicated sales force for neurology and psychiatry, and seeking partners for primary care and ex-US markets.
Note to Editors: Business Wire’s PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire’s online event calendar. For information, email tradeshow (at) businesswire.com.
Comments